Table 2 |
||||
|
Phenotypic frequencies (carriership) of the three-allele combinations (trios) and their two-element subsets in Russian MS patients and healthy individuals |
||||
|
Allelic combinations |
MS patients, N (%) |
Controls, N (%) |
p-value# |
OR (95% CI)## |
|
|
||||
|
-509TGFβ1*C, DRB1*18(3), CTLA4*G (trio 1)* |
5 (5.3) |
0 (0) |
0.0086 |
18.0 (1.0–330) |
|
-509TGFβ1*C, DRB1*18(3) |
5 (4.4) |
2 (0.7) |
0.029 |
|
|
-509TGFβ1*C, CTLA4*G |
63 (61) |
102 (58) |
0.61 |
|
|
DRB1*18(3), CTLA4*G |
5 (3.0) |
2 (1.1) |
0.26 |
|
|
|
||||
|
-238TNF*B1,-308TNF*A2, CTLA4*G (trio 2)** |
11 (8.7) |
0 (0) |
0.0033 |
17.4 (1.1–300) |
|
-238TNF*B1,-308TNF*A2 |
13 (9.9) |
6 (5.4) |
0.26 |
|
|
-238TNF*B1, CTLA4*G |
38 (30) |
15 (17) |
0.036 |
|
|
-308TNF*A2, CTLA4*G |
26 (16) |
15 (14) |
0.73 |
|
|
|
||||
|
* 99 MS patients and 154 controls were genotyped at these polymorphic loci of TGFβ1, DRB1 and CTLA4 genes. ** 126 MS patients and 87 controls were genotyped at these polymorphic loci of TNF and CTLA4 genes. #p-values considered to be significant are given in bold face. ## OR (95% CI) values are shown for significant p-values. |
||||
|
Favorova et al. BMC Medical Genetics 2006 7:63 doi:10.1186/1471-2350-7-63 |
||||
